[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-control":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100609194","the-erector-spinae-plane-block-for-gastrointestinal-malignancy-pain-treatment-egipt-100609194",false,"NCT07211386","The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)","Efficacy of the Erector Spinae Plane Block for Abdominal Pain From Gastrointestinal Malignancies","EGIPT","Inclusion Criteria:\n\n1. Patients age \\> 18 years old with GI malignancy presenting to a Penn Medicine ED with intractable abdominal pain.\n2. Same-day or recent CT scan of the abdomen \u002F pelvis which demonstrates that the patient's abdominal pain can be reasonably attributed to a malignant source.\n\nExclusion Criteria:\n\n1. Allergy to ropivacaine or history of local anesthetic systemic toxicity.\n2. Pregnancy\n3. Incarcerated\n4. Patients being admitted for serial abdominal examinations to determine their surgical course.\n5. Altered mental status or inability for patient to consent for the procedure\n6. Hemodynamic instability\n7. Previously enrolled in the study","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will target patients with gastrointestinal (GI) malignancy who present to any of 4 Penn Medicine emergency departments (EDs) with intractable abdominal pain. We will offer eligible patients an erector spinae plane block (ESPB), a regional anesthesia technique which is already offered to such patients in the ED at the University of Pennsylvania Healthy System (UPHS), for their intractable abdominal pain. We will compare the outcomes of this prospective cohort of patients to a matched historical control of patients with GI malignancy who were treated in the ED during the same time period as recruitment, but who were not recruited to partake in the study and who were managed with standard of care. Opioid consumption as measured by total milligram morphine equivalents (MMEs) over a 24-hour period and hospital length of stay (LOS) will be compared between cohorts. Additionally, for the ESPB cohort, pain level pre\u002Fpost ESPB, and functionality and satisfaction with pain management at 24 hours will also be examined.",[27,28],"Gastrointestinal Malignancy","Pain Control",[30,31,32],"Gastrointestinal malignancy","pain control","nerve block","RECRUITING","2025-11-24",{"date":36,"type":37},"2025-11-28","ACTUAL",{"date":39,"type":21},"2025-12-11",{"date":41,"type":21},"2027-06-15",{"name":43,"class":44},"Abramson Cancer Center at Penn Medicine","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100591876","virtual-contexts-for-affective-modulation-100591876","NCT06986122","Virtual Contexts for Affective Modulation","Controllability of Virtual Contexts for the Modulation of the Affective Experience","VCAM","* No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis\n* No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis\n* No self-reported current chronic pain, or acute pain within three months of the study period\n* No current migraine disorder (i.e., 15 headache days or more in 1 month)\n* No use of central nervous system-effective medication or other medication for neurological\u002Fpsychiatric treatment\n* No self-reported substance abuse within the last six months\n* No contraindication to MRI (e.g., pregnancy, claustrophobia, pacemakers, ear\u002Fcochlear implants, shrapnel injuries, clips, or other ferromagnetic\u002Felectrical objects\u002Fdevices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)\n* No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)\n* Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English\n* Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)",true,"55 Years",{"count":56,"type":21},20,[24],"This study investigates how spatial context and perceived controllability modulate pain, affective states such as anxiety, and motivated behavior. The study examines how control over pain and threat-related environments influences pain perception, state anxiety, associated autonomic responses, and behavior. The main questions it aims to answer are:\n\nDoes having control over pain within specific contexts alter how much pain people feel-even when the stimulus intensity remains constant? How do different types of environments (safe, controllable, or uncontrollable) shape pain-related brain activity, subjective anxiety, and physiological arousal? How do people perform cognitively demanding or distracting tasks (and retain their memory) when under threat versus when in control? Lastly, how do these learned associations with spatial contexts persist or adapt when environmental contingencies are explicitly changed?\n\nTaken together, exploration of these factors may lay the groundwork for understanding how placebo-related mechanisms-including perceived control, contextual learning, emotional engagement, and distraction-interact to shape pain and anxiety in complex environments.",[28,60,61],"Anxiety","Memory",[63,64],"Place conditioning","controllability of pain","2025-10-29",{"date":67,"type":37},"2025-10-31",{"date":69,"type":37},"2025-10-28",{"date":71,"type":21},"2029-06-15",{"name":73,"class":44},"Trustees of Dartmouth College",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":74},"100602227","phase-3-pain-control-alternatives-in-pediatric-patients-with-distal-radius-fractures-100602227","NCT07120763","Pain Control Alternatives in Pediatric Patients With Distal Radius Fractures","Inclusion Criteria:\n\n* Children requiring reduction for distal radius fracture\n* Children presenting to the emergency department\n* Children who are ages 3 to 17 years.\n\nExclusion Criteria:\n\n* Pediatric patients \\\u003C3 years old\n* Adult patients (i.e. ages 18 or up)\n* Pediatric patients with injury patterns that are not amenable to hematoma block.\n* Children who are not a candidate for sedation related to BMI \\> 95%tile for age, ASA class \\> 2, Mallampati score \\> 2, and pregnant patients","3 Years","17 Years",{"count":84,"type":21},50,[86],"PHASE3","The aim of this study is to evaluate the efficacy of a hematoma block and minimal ketamine pain control or hematoma block and intranasal fentanyl in pediatric patients presenting with distal radius fractures requiring reduction, compared to control of standard full conscious sedation using ketamine.",[89,28,90],"Distal Radius Fracture Reduction","Pediatric Fractures","2025-10-08",{"date":93,"type":37},"2025-10-10",{"date":95,"type":37},"2025-08-22",{"date":97,"type":21},"2027-08-22",{"name":99,"class":44},"State University of New York at Buffalo",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":74},"100607985","phase-4-rct-suzetrigine-vs-norco-for-post-op-pain-100607985","NCT07195669","RCT: Suzetrigine vs Norco for Post-op Pain","Nonopioid Versus Opioid Management of Post-operative Pain Following Oral & Maxillofacial Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-45 years requiring extraction of impacted mandibular bilateral third molar teeth, uncomplicated mesioangular impacted teeth, or vertical impaction of unerupted and impacted mandibular third molars.\n* Patients aged 18-45 years undergoing bimaxillary orthognathic surgery.\n\nExclusion Criteria:\n\n* Pregnant or nursing, history of prior opioid abuse, have history of temporomandibular dysfunction or local myofascial pain disorder preoperatively, with history of congenital syndrome requiring previous surgeries, orthognathic revisions, have a bleeding disorder, cannot receive instruction in English, are currently utilizing analgesics for another painful condition","45 Years",{"count":109,"type":21},76,[111],"PHASE4","Journavx (suzetrigine) is a novel non-opioid analgesic that is FDA approved for acute pain management and may offer a promising alternative for managing postoperative pain. Suzetrigine is selective inhibitor of the sodium channel NaV1.8, for managing acute pain. NaV1.8, a sodium channel, plays a key role in transmitting pain signals. Importantly, this channel is minimally expressed in the brain, enabling effective pain control without the potential central nervous system side effects of respiratory depression and addiction associated with opioids. Clinical trials have shown Journavx to be effective in managing moderate to severe post-operative pain equal to that of opiates. This study aims to further evaluate the efficacy and safety of Journavx in managing post-operative pain after third molar removal and orthognathic surgery.\n\nParticipants in this study should be aged 18-45 without significant autoimmune diseases, chronic kidney disease, liver disease, chronic pain disorder including temporomandibular joint disorder, bleeding disorders, pregnant or nursing, undergoing either extraction of both lower third molars or orthognathic surgery of both the maxilla and mandible.",[28],[115,116,117],"pain","analgesic","post-operative","NOT_YET_RECRUITING","2025-09-24",{"date":121,"type":37},"2025-09-29",{"date":123,"type":21},"2025-10-01",{"date":125,"type":21},"2026-01-30",{"name":127,"class":44},"Jacob Lensing"]